Ed Silverman is a Pharmalot columnist and senior writer at STAT. With three decades of experience covering the pharmaceutical industry, he focuses on themes such as pharmaceuticals, healthcare systems, and the intersection of business and health. Ed has been featured in notable publications including The Boston Globe and STAT News, and he is a recipient of the Gerald Loeb Award for his impactful commentary on business journalism.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ed Silverman's articles predominantly revolve around the healthcare and pharmaceutical industry, with a specific focus on government announcements, legal policy regulations, and data citations. His coverage suggests he would be most receptive to pitches offering insights into regulatory developments impacting the pharmaceutical industry.
Given his coverage of comings and goings within the industry, Ed may also be interested in news relating to executive appointments or departures at prominent pharmaceutical companies.
As there is no specified geographic focus for Ed's work, it is advisable to provide information relevant to global trends or developments within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ed Silverman
Save stories to read later, available anytime from your account.
Save stories to read later, available anytime from your account.
By: Ed Silverman
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
By: Ed Silverman
Save stories to read later, available anytime from your account.
By: Ed Silverman
Save stories to read later, available anytime from your account.
By: Ed Silverman
Missouri AG told Lilly to stop forcing hospitals to provide claims data to receive discounted medicines under 340B, a sign more states are pushing back against drugmakers.
By: Ed Silverman
An Incyte drug, when combined with chemo, induced lasting pancreatic tumor responses Rise and shine, everyone, another busy day is on the way.
By: Ed Silverman
Save stories to read later, available anytime from your account.
By: Ed Silverman
A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money.
By: Ed Silverman
Save stories to read later, available anytime from your account.
